News > Bharat Biotech Hopes Covaxin to be at least 60% Effective, Aims to Launch Vaccine in Q2 of 2021
Bharat Biotech Hopes Covaxin to be at least 60% Effective, Aims to Launch Vaccine in Q2 of 2021
![](https://assets-news-bcdn.dailyhunt.in/cmd/resize/700x415_80/fetchdata16/images/b1/a5/3a/b1a53a21d9777c5cb89745f9a7caaca447efd4b668bd7d9848a64f416731db8e.jpg)
Newsdig | 22/11/2020 01:04 PM | Click to read full article
India’s indigenous Coronavirus vaccine maker Bharat Biotech has said that they are expecting the immune shots to be at least 60 per cent effective.
Sai D Prasad, President, Quality Operations at Bharat Biotech, said, “The WHO, US FDA and even India’s Central Drugs Standard Control Organisation approve a respiratory vaccine if it achieves 50 per cent efficacy. For Covaxin, we aim to achieve at least 60 per cent but, it could also be more.”